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The p63 gene encodes a master regulator of epidermal commitment,
development, and differentiation. Heterozygous mutations in the
C-terminal domain of the p63 gene can cause ankyloblepharon-
ectodermal defects-cleft lip/palate (AEC) syndrome, a life-threatening
disorder characterized by skin fragility and severe, long-lasting skin
erosions. Despite deep knowledge of p63 functions, little is known
about mechanisms underlying disease pathology and possible treat-
ments. Here, we show that multiple AEC-associated p63 mutations,
but not those causative of other diseases, lead to thermodynamic pro-
tein destabilization, misfolding, and aggregation, similar to the known
p53 gain-of-function mutants found in cancer. AEC mutant proteins
exhibit impaired DNA binding and transcriptional activity, leading to
dominant negative effects due to coaggregation with wild-type
p63 and p73. Importantly, p63 aggregation occurs also in a condi-
tional knock-in mouse model for the disorder, in which the mis-
folded p63 mutant protein leads to severe epidermal defects.
Variants of p63 that abolish aggregation of the mutant proteins
are able to rescue p63’s transcriptional function in reporter assays
as well as in a human fibroblast-to-keratinocyte conversion assay.
Our studies reveal that AEC syndrome is a protein aggregation
disorder and opens avenues for therapeutic intervention.
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As a tetrameric transcription factor required for the devel-opment of stratified epithelia, p63 plays an essential role in
the commitment of simple ectoderm to epidermal lineages and
in the proliferative potential of epidermal stem cells (1–6). Its
DNA binding domain (DBD) is highly homologous to the DBD
of its family members, p53 and p73. Therefore, p63 binds to
canonical p53 DNA-binding sites and shares some biological
functions with the other members of the family (7, 8). The highly
conserved oligomerization domain (OD) allows homotetrame-
rization required for high DNA affinity (9), and hetero-
tetramerization with p73 (10, 11). Due to the presence of two
independent promoters, two classes of p63 proteins are
expressed that differ at the amino (N)-terminus: TAp63 and
ΔNp63. TAp63 protein is highly expressed in a dimeric inactive
conformation in female germ cells during meiotic arrest (12, 13).
DNA damage promotes the formation of active tetramers (9),
leading to DNA damage-induced oocyte death (12). In contrast,
the ΔNp63 proteins are found in a tetrameric form, and are
primarily expressed in the basal regenerative layers of the epi-
dermis and other stratified epithelia, where they play multiple
essential roles in keratinocyte proliferation, differentiation, and
cell adhesion (3, 5, 7, 14, 15). For most epidermal target genes,
ΔNp63 acts as a transactivator, but it can also act as a repressor
for other genes (3, 5, 16–19).
At least three distinct 3′ splice variants also exist: α, β, and γ.
The α isoform is by far the most abundant isoform in stratified
epithelia and contains a poorly characterized sterile-α-motif (SAM)
domain, a putative protein interaction module present in a wide
variety of proteins, and a post-SAM (PS) domain. The p63 SAM
domain shows a typical five-helix bundle architecture (20, 21), is
unable to form homodimers (21, 22), and its function remains un-
known. The PS domain is about the same length as the SAM
domain and can be divided in two subdomains. The N-terminal
subdomain (45 amino acids) contains a transcriptional inhibitory
(TI) sequence that forms a closed inactive dimer with the TA do-
main (23, 24). The C-terminal subdomain (25 amino acids) contains
a sumoylation site involved in regulating p63’s concentrations (24).
Heterozygous mutations in p63 (TP63) are causative of a group
of autosomal dominant human disorders characterized by various
combinations of ectodermal dysplasia, orofacial clefting, and limb
malformations (7, 25). Among these disorders, ectrodactyly, ec-
todermal dysplasia, and cleft lip/palate syndrome [EEC, Online
Mendelian Inheritance in Man (OMIM) 604292] is mainly char-
acterized by severe ectrodactyly and limb defects (26), whereas in
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(AEC, OMIM 106260), the distinguishing features are anky-
loblepharon, congenital erythroderma, skin fragility, atrophy,
palmoplantar hyperkeratosis, and extensive skin erosions (21, 27).
Distinct p63 mutations can also cause nonsyndromic diseases, in-
cluding isolated split hand/foot malformation (SHFM4, OMIM
605289) (28). For each of these diseases, mutations are generally
clustered in specific p63 protein domains or are found in the same
domain but have distinct characteristics, suggesting a genotype-
to-phenotype correlation (25) (Fig. 1A). AEC syndrome muta-
tions are predominantly clustered in the C-terminal portion of
p63, either as missense mutations in the SAM domain and more
rarely in the TI domain, or as single-base frameshift mutations
that lead to elongation of the C-terminal domain (25).
It is generally believed that heterozygous p63 mutations have a
dominant-negative effect due to formation of mixed wild-type and
mutant p63 tetramers, reducing the cellular amounts of functional
p63. The fact that different mutations give rise to distinct phe-
notypes and syndromes, however, suggests distinct mechanisms of
action of the mutants. Here, we report that the dominant-negative
activity effects of AEC-associated p63 mutations result from an
increased aggregation propensity. Mutant p63 induces misfolding
and coaggregation of wild-type p63, causing partial impairment in
DNA binding and deficient transcription of target genes. This is
observed both in heterologous cells expressing AEC mutant p63
proteins and in keratinocytes derived from a newly developed con-
ditional knock-in mouse model for AEC syndrome. Mutant p63 also
leads to coaggregation with its paralogue p73, possibly also leading
to its inactivation. Relieving mutant p63 aggregation leads to
reactivation of its function, indicating that aggregation is the cause
of its impairment.
Results
Aggregation Is a Characteristic Feature of AEC Mutant p63 Proteins.
AEC mutations cluster predominantly in the carboxyl (C) termi-
nus of the p63α isoform and include several missense mutations in
the SAM domain (e.g., L514F, G530V), two missense mutations
in the TI domain (R598L, D601V), and several frameshift muta-
tions leading to abnormal extensions of the C terminus (e.g., 3′ss
intron 10, 1456InsA, 1709DelA, 1859DelA) (Fig. 1A). In contrast,
the few EEC mutations found in the C terminus cause a pre-
mature stop codon (Fig. 1A), suggesting that missense mutations,
extensions, or truncations of the C terminus differentially alter
p63 function. The mechanisms by which AEC-causative mutations
interfere with p63 functions has remained obscure, and we hy-
pothesized that a selective structural alteration may be at the basis
of this disorder. To test this hypothesis, we first determined the
structure of L514F mutant SAM domain using NMR (Fig. 1B and
SI Appendix, Fig. S1A and Table S1). L514 is a highly conserved
amino acid in the first helix of the SAM domain, which is mutated
to phenylalanine, serine, or valine in AEC patients (21, 29). The
wild-type and L514F mutant structures revealed close similarity,
with a backbone root mean square deviation (rmsd) value of 1.5 Å.
The less compact fold of the mutant protein was caused by steric
clashes due to the placement of the phenylalanine side chain in
the hydrophobic core as previously predicted (30), likely leading to
destabilization of the SAM domain.
To measure SAM domain destabilization, we monitored
temperature-induced unfolding by circular dichroism (CD) spec-
troscopy (Fig. 1C). While the wild-type SAM domain showed a
melting temperature of 79 °C, the mutant was destabilized with an
unfolding temperature of 65 °C. In addition, only the unfolding of
the wild-type SAM domain was reversible, while the L514F SAM
domain mutant irreversibly precipitated upon unfolding (Fig. 1D
and SI Appendix, Fig. S1B).
To investigate whether AEC mutants might be prone to de-
stabilization and precipitation due to an increased aggregation
propensity, we analyzed the p63 amino acid sequence using the
TANGO algorithm that predicts aggregation prone regions
(APRs) in proteins (31). This analysis indicated that two pep-
tides (peptides 1 and 2), located in the first and third helix of
the SAM domain, displayed some aggregation propensity, which
was enhanced by the L514F and G530V mutations, respectively
(Fig. 1E, Lower and SI Appendix, Fig. S1C and Table S2). Sim-
ilarly, the two point mutations within the TI domain, R598L and
D601V, strongly enhanced the low intrinsic aggregation pro-
pensity of the TI domain (Fig. 1E, Lower and SI Appendix, Table
S2). Finally, TANGO analysis was performed for 3′ss-int10 and
1456InsA, and on the 1709DelA and 1859DelA mutants that
lead to frameshifts and two different extensions of the C terminus,
respectively. Aberrant elongations of the mutant proteins gener-
ated APRs (peptides I, II, III) (Fig. 1E and SI Appendix, Fig. S1D
and Table S2). In contrast, EEC-associated frameshift mutations in
the C terminus 1572InsA, 1576DelTT, and 1743DelAA did not
create new peptides predicted to lead to aggregation (SI Appendix,
Table S2), suggesting that the generation, exposure, or enhance-
ment of APRs is a characteristic feature of AEC syndrome.
To assess whether AEC-associated mutant p63 proteins have
the propensity to form aggregates in mammalian cells, wild-type
and mutant p63 were overexpressed in H1299 cells that are devoid of
p53 and its family members, and run on Blue-Native polyacrylamide
gel electrophoresis (BN-PAGE) followed by Western blotting.
Transiently overexpressed wild-type p63 and EECmutations (R304Q,
1576DelTT, 1743DelAA, 1572InsA) run primarily as monomers (Fig.
1F), in agreement with the short half-life of the p63 tetramer com-
pared with that of other p53 family members (32). In contrast,
overexpression of p63L514F and all other tested AEC mutants
caused a shift in molecular mass, consistent with the formation of
large multimeric assemblies (Fig. 1F). Such aggregation was sim-
ilar to that observed for the conformation mutant of p53 (R175H),
known to be destabilized and to aggregate (33), whereas the p53
DNA contact mutant R248W did not aggregate (SI Appendix, Fig.
S1E). Similar results were obtained by size exclusion chromatog-
raphy (SEC), in which most of the p63L514F mutant protein eluted
at high molecular weight (Fig. 1G) similarly to p53R175H mutant
protein (SI Appendix, Fig. S1G), whereas wild-type p63 eluted at
low molecular weight.
AEC Mutant p63 Selectively Binds to p53 Family Members. The on-
cogenic gain-of-function activities attributed to mutant p53 have
been correlated to aberrant binding and coaggregation with wild-
type p63 and p73 (33). We previously reported that binding of
p53 mutants to p63 is dependent on the low but detectable ag-
gregation tendency of the p63 TI domain (Fig. 1E and SI Ap-
pendix, Table S2) (32). Such aggregation tendency is completely
abolished by the p63V603D mutant that is unable to bind p53 (32).
To test whether the aggregation propensity of AEC mutants in the
SAM domain is dependent on the mild intrinsic aggregation pro-
pensity of the TI domain, we tested AECmutants in the background
of the V603D mutation. All AEC mutants in the SAM domain
exhibited severe aggregation even in the V603D background, while
the wild-type and EEC mutants (R279H, R304Q) displayed no
residual aggregation as shown by BN-PAGE and SEC (Fig. 2 A
and B). Accordingly, AEC-associated mutants strongly bound to
mutant p53 even in the V603D background, whereas no binding
was observed for EEC mutants (Fig. 2C). Aggregation of AEC
mutants was temperature-dependent, as p63L514F/V603D ag-
gregation progressively increased at physiological temperature,
whereas no aggregation was observed in either p63V603D or
p63R304Q/V603D even at high temperature (SI Appendix, Fig.
S2A). Taken together, these data indicate that AEC mutants have
a strong tendency of aggregating, and that AEC mutations in the
SAM domain cause aggregation independently of the TI domain.
To investigate whether AEC-associated mutant p63 may coag-
gregate with wild-type p63, we cotransfected HA-tagged wild-type
p63 with Myc-tagged wild-type or AEC mutant p63. Interest-
ingly, even in the V603D background, the SAM domain mutant
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Fig. 1. Aggregation propensity of AEC mutant p63. (A) p63 structure and disease-causative mutations (color-coded for each disease as indicated). In bold are
mutations used in this study. (B) NMR spectroscopy of the murine L514F SAM (PDB ID code 5N2O). Bundle of 20 conformers with the lowest CYANA target
function values is shown. The mutated amino acid is indicated as a stick. (C) Melting curves of the purified wild-type (black) and L514F (red) SAM domain were
recorded by CD spectroscopy. (D) Reverse CD melting curves of the purified wild-type and L514F SAM domain after recording the initial melting curve. The
mutant remained unfolded due to irreversible precipitation. (E) TANGO analysis for the wild-type ΔNp63α (in black) and for the indicated AEC mutations
caused by protein elongation (Upper: aggregating peptide I-III) or missense mutations in the SAM and TI domains (Lower). The V603D variant is predicted to
abolish mutant aggregation. (F) BN-PAGE (Upper) and SDS/PAGE (Lower) followed by Western blot for p63 in H1299 extracts expressing wild-type (WT) and
the EEC (blue) or the AEC (red) mutations. Soluble ΔNp63α protein runs mainly as a monomer (m). (G) SEC followed by Western blot of H1299 cell lysates
overexpressing wild-type ΔNp63α and p63L514F mutant. Samples were incubated at 37 °C for 15 min before loading on SEC. Bar diagrams on the Left show
the relative intensities of each collected fraction.
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aggregated with wild-type p63 (SI Appendix, Fig. S2B), indi-
cating that it may exert a dominant negative function.
As previously shown for wild-type p63 (10, 11), AEC mutant p63
bound p73 (SI Appendix, Fig. S2C). A p73 mutant protein with no
propensity to self-aggregate (p73V586D) (32) aggregated in the
presence of mutant p63L514F/V603D, but not with p63V603D
alone (Fig. 2D). In contrast neither wild-type nor AECmutant p63
interacted with wild-type p53 (SI Appendix, Fig. S2D), and no increase
in p53 aggregation was observed in the presence of AEC mutant p63
(SI Appendix, Fig. S2E). Taken together, these data indicate that
AEC-associated p63 mutants cause aggregation not only of their
wild-type p63 counterpart, but also of wild-type p73, revealing
that AEC-associated p63 mutants may display gain-of-function
activities through coaggregation with selected family members.
Protein Aggregation Is Associated with Impaired Transcriptional
Function in a Mouse Model for AEC Syndrome. To investigate the
effect of AEC-associated mutations on ΔNp63α function, we tested
the ability of a variety of mutants (Fig. 1A) to transactivate the
regulatory regions of two crucial p63 target genes, namely keratin 14
(KRT14) and fibroblast growth factor receptor 2 (FGFR2) (15, 34,
35). As previously reported (15, 36), wild-type ΔNp63α efficiently
activated the KRT14 promoter as well as the FGFR2 enhancer in
HEK293 cells, whereas an EEC causative mutation that directly
impairs DNA binding (R304Q) abolished p63 activity (SI Appendix,
Fig. S3A). All tested AEC-associated mutations, including missense
mutations in the SAM and TI domains and frameshift mutations,
invariably abolished or severely reduced p63 transcriptional ac-
tivity, whereas two missense mutations in the PS domain causative
of SHFM syndrome (Q630X and E635X) retained transactivation
activity in this context.
To test whether impaired transcriptional activity of AEC-
associated p63 mutants affected its biological function in a more
physiological context, we took advantage of a recently developed
protocol to convert human dermal fibroblasts (HDFs) into induced
keratinocyte-like cells (iKCs) by coexpression of ΔNp63α and
Krüppel-like factor 4 (KLF4) (37). Eighteen days after p63/KLF4
transduction, HDFs had converted into iKCs and expressed
keratinocyte-specific p63 transcriptional targets, including KRT14
(5, 35), the IFN regulatory factor 6 (IRF6) involved in keratino-
cyte differentiation (38–40), and desmocollin 3 (DSC3) encoding a
desmosome component expressed in basal keratinocytes (14) (Fig.
3 A and B). In contrast, similarly to the EEC mutant R304Q, AEC
mutants were unable to induce expression of keratinocyte-specific
target genes, indicating that they are functionally incapable to
convert HDFs into iKCs.
To assess whether loss of p63 activity occurs in vivo, we generated
a mouse model for AEC syndrome. We have previously shown that
a constitutive p63 L514F knock-in mouse phenocopies the clinical
Fig. 2. AEC-associated p63 mutants aggregate with other p53 family members. (A) BN-PAGE (Upper) and SDS/PAGE (Lower) followed by Western blot of the
wild-type p63 and an extended set of AEC mutations in the SAM domain in the ΔNp63αV603D variant background (Left) and EEC mutant (Right) transiently
expressed in H1299 cells. (B) SEC analysis and Western blot of wild-type and the indicated mutant p63 expressed in H1299 cells. Wild-type ΔNp63α and all EEC
mutant proteins elute as tetramers (11.25–15 mL), while AEC mutants are mainly shifted to the void volume (7.5 mL), corresponding to aggregates. (C) Coim-
munoprecipitation between mutant HA-p53R175H and the indicated Myc-ΔNp63α proteins. p53 was immunoprecipitated (IP) with an HA-specific antibody. Anti-
HA Tag antibodies were used to detect p53, whereas anti-Myc antibodies were used for p63. (D) SEC analysis and Western blot of ΔNp73α V586D (corresponding
to V603D in p63) coexpressed with ΔNp63α V603D either wild-type or L514F in H1299 cells. Samples were incubated at 37 °C for 15 min before loading on SEC.
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hallmarks of the human disorder at least in part through impaired
FGFR2 signaling required for the expansion of epidermal pro-
genitor cells during embryonic development (15, 41). However, the
constitutive p63 L514F knock-in mouse line could not be main-
tained due to fully penetrant cleft palate and consequent perinatal
lethality (15). Therefore, we used a conditional knock-in strategy to
create L514F mutant mice (p63L514Fflox/L514Fflox) in which the AEC-
associated mutation L514F is only expressed in the presence of Cre
recombinase (Fig. 3 C and D, and SI Appendix, Fig. S3 B–D). We
first tested the expression of p63 target genes in primary keratino-
cytes isolated from p63L514F mice infected with an adenovirus
carrying the Cre recombinase (Ad-Cre) or a mock control. Target
genes previously reported to be positively regulated by p63 and
affected in AEC syndrome (14, 15, 35, 40, 42) were strongly reduced
in Ad-Cre–infected homozygous keratinocytes and to a lesser extent
in heterozygous keratinocytes compared with Ad-GFP controls
(Fig. 3 E and F), confirming that endogenous mutant p63L514F has
an impaired transactivation ability. Interestingly, expression of genes
repressed by p63, such as Smad7 and Krt8 (5, 17) were derepressed
in the presence of the L514F mutant compared with controls (Fig.
3G), demonstrating that both transactivation and repression func-
tions of p63 are impaired by AEC mutations.
p63L514Fflox/L514Fflox mice were crossed with K14-Cre knock-in
mice carrying the Cre recombinase under the control of the en-
dogenous Krt14 promoter that is active in stratified epithelia from
embryonic day 17.5 (43), leading to uniform p63 mutant expres-
sion from P0 (Fig. 3H). K14-Cre; p63L514Fflox/L514Fflox homozygous
mice displayed ectodermal defects and skin erosion typical of
AEC syndrome (Fig. 3I). Primary keratinocytes isolated from
K14-Cre; p63L514Fflox/L514Fflox mice exhibited strongly decreased
levels of crucial p63 target genes (Fig. 3J).
To test whether mutant p63L514F protein exhibited propensity
toward aggregation endogenously, we performed BN-PAGE fol-
lowed by Western blotting on keratinocyte lysates. As expected, p63
from wild-type keratinocytes mainly runs as a monomer. In contrast,
the monomeric form was reduced and large multimeric assem-
blies were observed in Ad-Cre–infected p63+/L514Fflox keratinocyte
lysates, whereas in Ad-Cre–infected p63L514Fflox/L514Fflox kera-
tinocyte lysates, the monomeric form was lost (Fig. 3K). Similar
results were observed with primary keratinocytes derived from
Krt14-Cre;p63+/L514Fflox and Krt14-Cre;p63L514Fflox/L514Fflox
mice compared with p63L514Fflox/L514Fflox controls (Fig. 3L).
Taken together these data indicate that AEC-associated p63
mutations impair the ability of p63 to act both as a transcriptional
activator and as a repressor in vivo, and that the impairment is
associated with progressive p63 aggregation in the presence of the
mutant form.
Aggregation of AEC-Associated p63 Mutants Causes Impaired DNA
Binding. To test whether aggregation of AEC mutants alters the
ability of p63 to bind DNA, chromatin immunoprecipitation followed
by quantitative PCR (ChIP-qPCR) was performed in HEK293 cells
transfected with wild-type and/or mutant p63. As previously reported,
the EEC-associated mutant R304Q did not bind to well-characterized
p63 genomic binding sites in KRT14, and p63 genes that are positively
regulated by p63, or to a p63 binding site in the CDKN1A promoter
negatively regulated by p63 (3, 5, 15, 44, 45) (Fig. 4A and SI Appendix,
Fig. S4 A–E). Surprisingly, even though the AEC mutations do not
fall in the DNA binding domain, reduced DNA binding was observed
for all AEC-associated mutants, whereas the SHFM-associated mu-
tants efficiently bound DNA. DNA binding was also impaired when
wild-type p63 was cotransfected with the L514F mutant, indicating
that the mutant exerts a dominant negative effect on p63 DNA
binding (Fig. 4B). Similarly reduced DNA binding was observed
by electrophoretic mobility shift assay (EMSA) in HEK293 nu-
clear extracts (SI Appendix, Fig. S4F).
To assess the physiological relevance of these findings, the
ability of p63 to bind DNA was tested in mouse primary kera-
tinocytes within previously characterized p63 binding sites for
positively regulated genes (Irf6, Fgfr2, and Trp63) (15, 40, 44) or
for a negatively regulated gene Smad7 (17). A significant reduction
in p63 binding to DNA was detected in p63L514Fflox/L514Fflox knock-
in keratinocytes, infected with Ad-Cre compared with controls for
all tested binding sites (Fig. 4 C and D). Taken together these data
indicate that the ability of p63 to bind DNA is weakened by mu-
tations in the p63 C terminus causative of AEC syndrome.
To evaluate if reduced DNA binding is due to aggregation, we
performed DNA pulldown experiments of in vitro translated pro-
teins under conditions in which all mutant and wild-type proteins
had a tetrameric conformation and did not form aggregates as
assessed by SEC (SI Appendix, Fig. S4G). While EEC mutants
R204W and R304Q had an intrinsic DNA binding impairment,
AEC mutants L514F and G530V efficiently bound to DNA at
similar levels as the wild-type protein (Fig. 4E).
Taken together, these results indicate that the DNA binding
ability of AEC mutants is not intrinsically impaired, but rather is
weakened, likely due to structural alterations and consequent pro-
tein aggregation that occurs in cells.
Transcriptional Activity Is Restored by Reducing the Aggregation
Propensity of AEC-Associated Mutant p63. We next investigated
whether reversing aggregation would be sufficient to restore tran-
scriptional activity of AEC mutants. To this end we introduced
point mutations predicted by TANGO to alleviate aggregation,
or we deleted APRs. For the p63L514F mutant, aspartic acids
were introduced in each of the two APRs in the SAM domain of
the p63L514F mutant (Fig. 1E, SAM peptide 1 and 2, SI Appendix,
Fig. S5A and Table S3). Aggregation was alleviated to various ex-
tents upon introducing single mutations in either peptide (V511D
or F513D for peptide 1, and T533D or I534D for peptide 2), or
combinations V511D/I534D, F513D/T533D, and F513D/I534D.
Importantly, the double V511D/T533D substitution completely
abolished aggregation of the L514F mutant (Fig. 5A). Next, we
deleted APRs generated by frameshift mutations (Fig. 1E and SI
Appendix, Fig. S1D). Deletion of peptide I for the splice mutant 3′
ss-int10, peptide II and III for the 1709DelA, and peptide III for
the 1859DelAV603D frameshift mutants completely inhibited their
aggregation (Fig. 5B and SI Appendix, Fig. S5B). Finally, we tested
the possibility that the V603D mutation could abolish the aggre-
gation propensity of the adjacent mutations R598L or D601V in
the TI domain as predicted by TANGO (SI Appendix, Fig. S5A and
Table S2). Introduction of the V603D mutation indeed inhibited
aggregation of the R598L or D601V completely or to a large ex-
tent, respectively (Fig. 5C).
We next used transactivation assays to test whether abolishing ag-
gregation rescued the transcriptional activity of p63 mutants. Consis-
tent with the aggregation data, L514F and L514F/V603D mutants
were inactive in luciferase assays, whereas L514F/V603D bearing the
V511D/T533D double mutation exhibited restored transcriptional ac-
tivity (Fig. 5D). Similarly, p63 transcriptional activity was fully restored
upon deletion of the APRs in the elongated C-terminal domain caused
by the frameshift mutations 1709DelA and 1859DelA (Fig. 5E).
Finally, the V603D variant completely rescued the activity of the
two point mutants R598L and D601V in the TI domain (Fig. 5G).
The weakened ability of the aggregation mutants to execute
transcriptional modulation might explain the disease phenotype
observed in AEC patients. To directly test the functional conse-
quence of the increased aggregation for keratinocyte homeostasis,
we resorted to the HDF to iKC conversation assay that is other-
wise impaired by AEC mutations (Fig. 3 A and B). Deleting
the aggregation peptides of the 1709DelA mutant or introducing
V603D into the R598L mutant fully rescued their ability to induce
expression of KRT14 and IRF6 in HDF (Fig. 5G and H). Similarly,
alleviating aggregation of the p63L514F mutant rescued its ability to
convert HDF to iKC (Fig. 5H).
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Finally, when exogenously expressed in wild-type keratinocytes,
deleterious mutants p63L514F and p63R598L led to partial p63
aggregation and induction of Krt8 expression, a marker of simple
epithelial tissues repressed by wild-type p63 and aberrantly expressed
in knock-in mutant keratinocytes (Fig. 3G) (5). Importantly, p63 ag-
gregation and Krt8 expression were suppressed by expression of res-
cue mutants (p63L514FV603D/V511D/T533D and R598LV603D)
(SI Appendix, Fig. S5 C and D).
Fig. 3. p63 aggregation and impaired transcriptional function in a mouse model of AEC syndrome. (A) Real-time RT-PCR of the indicated keratinocyte-specific
p63 target genes in HDFs converted to iKCs by coinfection with Klf4 and the indicated p63 viruses. (B) Western blot of Krt14 and p63 in iKCs. β-actin was used as
loading control. (C) Gene targeting strategy for the p63+/L514Fflox knock-in mice. Mutant exon 13 carrying the L514F mutation is indicated in red. LoxP sites (black
triangles) flank wild-type exon 13 (green) fused with the coding portion of exon 14 and the SV40 polyA (pA). 3xFLAG (blue) was placed at the end of the coding
sequence in exon 14. FLAG-tagged p63 mutant protein is expressed upon Cre mediated deletion. (D) Real-time RT-PCR of wild-type p63 (gray bars) and p63L514F
(white bars) in keratinocytes derived from p63+/floxL514F (het) and p63L514Fflox/L514Fflox (hom) mice after Ad-Cre–mediated deletion or after infection with Ad-GFP
(ctr). (E) Real-time RT-PCR of target genes induced by p63 in mutant keratinocytes with ctr levels set to 1 (n = 5). (F) Western blot for p63 and the protein products
of its target genes Krt14 and Irf6 in mutant keratinocytes. ERK was used as loading control. (G) Real-time RT-PCR of p63 repressed target genes in mutant
keratinocytes (n = 3). (H) Immunofluorescence for K14 (green) and FLAG-tagged p63L514F (red) in epidermis of wild-type (WT) and K14-Cre; p63L514Fflox/L514Fflox
(L/L) mice at P0. (Scale bars: 50 μm.) (I) Macroscopic phenotype of L/L mutant mice. Approximately 10% of newborn mice displayed large areas of skin erosions
(Left). Skin crusting and ulcerations with reduced body size and dehydration were observed at P7-P8 in 100% of mutant mice (Right). (J) Real-time RT-PCR of
p63 target genes in +/+ and L/L epidermis (n = 6). (K) BN-PAGE (Upper) and SDS/PAGE (Lower) followed by Western blot for p63 in mouse primary keratinocytes
infected with Ad-Cre or Ad-GFP as in D. (L) BN-PAGE (Upper) and SDS/PAGE (Lower) followed byWestern blot for p63 in primary keratinocytes isolated frommice
with the indicated genotypes. Data are shown as mean ± SEM with the exception of D in which error bars indicate SD. Statistical significance was assessed using
paired two-tailed t test (J) and one-way ANOVA analysis (A, E, and G). *P ≤ 0.05; **P ≤ 0.001; ***P ≤ 0.0001.
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Taken together, these data indicate that missense mutations in
the SAM domain or TI domain, or frameshift mutations leading to
AEC syndrome, cause p63 protein aggregation and loss of tran-
scriptional activity. Alleviating aggregation by mutating or removing
amino acids responsible for the aggregation is sufficient to restore
p63 transcriptional function.
Discussion
Among the p63-associated disorders, AEC syndrome is uniquely
characterized by long-lasting and life-threatening skin erosions.
Despite the severity of the symptoms, molecular studies have been
hampered by the paucity of human biological material, and the poor
understanding of the molecular mechanisms underlying the disor-
der. Here, we have shown that p63 mutations associated with AEC
syndrome cause reduced DNA binding and transcriptional activity
due to mutant protein aggregation. Aggregation is caused by either
aberrant protein elongation introducing aggregation-prone pep-
tides, enhancing the intrinsic low APR of the TI domain, or by
conformational changes that expose peptides with a natural high
aggregation propensity. The latter is equivalent to the well-known
gain-of-function mutations of p53 in cancer (e.g., R175H). AEC-
associated p63 mutant proteins coaggregate with their wild-type
counterpart and with p73. Importantly, the aggregation can be re-
versed and transcriptional activity of p63 rescued upon the in-
troduction of specific point mutations that disrupt aggregation-
prone peptides or upon their deletion.
To determine the relevance of these findings in vivo, we utilized
a newly developed mouse model for AEC syndrome. We showed
that endogenous mutant p63 in AEC mouse keratinocytes exhibits
aberrant aggregation and inactivation of both transcriptional ac-
tivating and repressing functions. This suggests that AEC muta-
tions are unlikely to selectively impair interactions between p63
and specific coactivators or corepressors, but rather cause protein
conformational changes that alter p63 function. The partial im-
pairment in DNA binding observed for AEC mutants indicates
that the propensity to form aggregates affects p63 affinity for
DNA. This impairment, however, is not an intrinsic property of
the AEC mutants but rather an indirect consequence of aggre-
gation. DNA binding impairment therefore depends on the degree
of aggregation and the effective removal of aggregates. This might
partially explain differences in severity of the symptoms observed
in different patients bearing the same mutation (25, 46), and dif-
ferences in severity between patients diagnosed with AEC syn-
drome and Rapp–Hodgkin syndrome (OMIM 129400), diseases
that have been suggested to be variable manifestations of the same
clinical entity caused by overlapping p63 mutations in the carboxyl
terminal domain (47, 48).
Aggregating proteins can inactivate other proteins through
coaggregation. Three categories of proteins affected by mutant
p63 can be distinguished. The first is wild-type p63 that exists in
heterozygous AEC patients. Due to the ability to form tetramers
through the tetramerization domain, mutant p63 can form com-
plexes with wild-type p63. Formation of aggregates by the mutant
protein also draws wild-type p63 into larger aggregates, thus
exerting a dominant negative effect. This effect was confirmed in
our experiments by showing that mutant p63 in L514F heterozy-
gous keratinocytes acts as a dominant negative inhibitor of wild-
type p63 function. The second category includes other p63 binding
partners. One example is the family member p73, which can form
heterotetramers with p63, consisting of one p63 dimer and one
p73 dimer. Structural studies have shown that p63/p73 hetero-
tetramers are thermodynamically more stable than either homo-
tetramer (49). Although the function of p63/p73 interactions in
skin biology remains uncharacterized, both proteins are expressed
simultaneously in the basal layer of the epidermis. While p63 is
abundant in all cells, p73 is more highly expressed in the fre-
quently dividing stem cell population (49, 50). The third category
includes proteins that normally do not interact or interact very
weakly with wild-type p63 but, due to the existence of hydrophobic
patches, can coaggregate with aggregating mutant p63. One exam-
ple is p53R175H, a structural mutant with gain-of-function prop-
erties that interacts with specific isoforms of p73 and, to a lesser
extent, of p63, interfering with their functions (32, 51, 52). The
p53R175H mutant interacts very weakly with wild type ΔNp63α
(refs. 32 and 51 and present study), whereas it interacts strongly with
AEC mutants. The biological significance of this interaction re-
mains to be determined. Since p63 is an abundantly expressed
transcription factor in keratinocytes, and AECmutants often show a
longer half-life in cells than the wild-type protein (36), mutant
Fig. 4. AEC-associated p63 mutant proteins exhibit impaired DNA binding in
cells. (A) ChIP-qPCR of the KRT14 promoter from HEK293 cells overexpressing
p63 wild-type (WT) and the indicated mutants (n = 6) (Upper) and SDS/PAGE
(Lower) followed by Western blot for p63 and β-actin (Lower). (B) ChIP-qPCR of
the p63 enhancer from HEK293 cells cotransfected with p63 WT and p63L514F
(n = 5) and relative SDS/PAGE (Lower) as in A. (C) ChIP-qPCR of the indicated p63-
responsive enhancers in primary keratinocytes derived from p63L514Fflox/L514Fflox
(hom) mice infected with Ad-Cre. Keratinocytes infected with Ad-GFP were
used as controls (ctr) (n = 4). (D) ChIP-qPCR of the indicated p63-repressed
gene element in primary keratinocytes under conditions as in C (n = 3).
(E) Pulldown (PD) assay and Western blot of in vitro translated p63 with
immobilized DNA oligonucleotides corresponding to the p63 responsive
element on the human CDKN1A promoter. Input (IP). Percentage of pull-
down efficiency is shown in the Right (n = 3). Data are shown as mean ± SEM
with the exception of E in which error bars indicate SD. Statistical signifi-
cance was assessed using paired two-tailed t test (C and D) and one-way
ANOVA (A, B, and E). *P ≤ 0.05; **P ≤ 0.001; ***P ≤ 0.0001.
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p63 may be able to sequester other nuclear proteins. Aggregation
between AEC mutants and p73 and/or other p63 protein partners
helps explain the severe skin phenotype specifically observed in
AEC syndrome and not in other diseases associated with
p63 mutations. Future studies should focus on identifying nuclear
proteins that may form large, inactive complexes with mutant p63.
By revealing that AEC syndrome is a protein aggregation disorder
and that aggregation can be reverted leading to a functional res-
cue, our studies open avenues for therapeutic intervention.
Materials and Methods
Detailed descriptions are provided in SI Appendix.
Mice. K14-Cre (Krt14-CreΔneo) knock-in mice were obtained from J. Huelsken,
Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland, and
were used to induce expression of the p63 mutant protein in stratified epi-
thelia at late stages of embryonic development (43). See SI Appendix for the
conditional knock-in mice (p63+/L514Fflox) generation. All mouse work was
conducted at CEINGE according to the Italian ethical regulations under the
animal license 311/2016-PR.
Fig. 5. Transcriptional activity is restored by reducing the aggregation propensity of AEC-associated mutant p63. (A–C) BN-PAGE (Upper) and SDS/PAGE
(Lower) followed by Western blot of p63 and the indicated mutations and deletions transfected in HEK 293 cells. (D–F) Luciferase reporter assays of wild-type
and mutant p63 on the KRT14 promoter in HEK293 cells (n = 3) (Upper). Luciferase data were normalized for Renilla luciferase activity. SDS/PAGE (Lower)
followed by Western blot of wild-type and mutant p63 are shown as control. (G) Real-time RT-PCR of the indicated keratinocyte-specific p63 target genes in
HDFs converted to iKCs by coinfection with KLF4 and the indicated p63 viruses. (H) Western blot of KRT14 and p63 in iKCs. β-actin was used as loading control.
Data are shown as mean ± SEM, and statistical significance was assessed using one-way ANOVA analysis. *P ≤ 0.05; **P ≤ 0.001; ***P ≤ 0.0001.
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Coimmunoprecipitation, SDS/PAGE, BN-PAGE. For coimmunoprecipitation, cells
were lysed in RIPA lysis buffer [20 mM Tris·HCl (pH 7.5), 150 mM NaCl, 1 mM
Na2EDTA, 1 mMEGTA, 1%Nonidet P-40, 1% sodium deoxycholate, 1 mMDTT]
with the addition of protease and phosphatase inhibitors. Lysates were cleared
by centrifugation and incubated with 2 μg of HA-antibody, p73 antibody, or
normal IgG overnight at 4 °C. The immunocomplexes were purified with 25 μL
of Protein G Dynabeads (Thermo Fisher Scientific) for 3 h at 4 °C. For SDS/
PAGE, cells were loaded in Laemmli sample buffer with 5% β-mercaptoetha-
nol. For BN-PAGE, cells were lysed in native lysis buffer [25 mM Tris (pH 7.5),
150 mMNaCl, 2 mMMgCl2, 20 mMCHAPS, 1 mMDTT and protease inhibitors].
Collected cells were incubated 1 h on ice in the presence of benzonase (Merck
Millipore). Protein extracts were then mixed with 20% Glycerol and 5 mM
Coomassie G-250 and loaded on 3–12% Novex Bis-Tris gradient gel for
BN-PAGE (Thermo Fisher Scientific). Antibodies used in this study are listed in
SI Appendix, Table S5.
Analytical SEC. Analytical SEC experiments were performed as previously
described (9, 32). Briefly, either a Superose 6 PC 3.2/300 column (GE
Healthcare) for in vitro translated p63 or a Superose 6 GL 10/300 column (GE
Healthcare) for cell lysates of transiently transfected H1299 cells were used.
H1299 cell lysate was prepared by three cycles of freezing and thawing in
SEC running buffer (50 mM Tris pH 7.5; 150 mM NaCl; 1 mM DTT) with
protease inhibitors and Benzonase followed by removal of cell debris by
centrifugation. Before injection, cell lysates were incubated at 37 °C for
15 min. The Superose 6 GL 10/300 column was calibrated using the Gel Fil-
tration HMW and LMW Calibration Kits.
RNA Isolation, RT-qPCR, and ChIP-qPCR. For RT-qPCR, total RNA was extracted
using TRIzol reagent (Thermo Fisher Scientific) and cDNA was synthesized
using SuperScript Vilo, Real time RT-PCRwas performed using the SYBRGreen
PCR master mix (Thermo Fisher Scientific) in an ABI PRISM 7500 (Thermo
Fisher Scientific). Target genes were quantified using specific oligonucleotide
primers (SI Appendix, Table S4) and normalized for mouse β-actin or human
RPLP0 expression. For ChIP-qPCR, chromatin was immunoprecipitated as
previously reported (44). Immunoprecipitation was performed using rabbit
antibodies for p63 or rabbit IgG as control. Bound chromatin was purified
with Protein A Sepharose (GE Healthcare) for 1 h at 4 °C. Bound DNA was
quantified by real-time PCR using specific oligonucleotide primers (SI Ap-
pendix, Table S4) and normalized to input.
CD Melting Curve. CD melting curves of p63 SAM or L514F mutant were
recorded with Jasco J-810 spectropolarimeter (Jasco Labortechnik). Changes
in CD signal at 222 nm and dynode voltage were recorded from 20 °C to 95 °C
and backward from 95 °C to 20 °C. Melting curves were corrected for the
pretransition phase and melting points were acquired using the Boltzman
sigmoidal fit function (Origin Pro-9.1G). To follow turbidity as an indicator of
precipitation and aggregation during unfolding, the dynode voltage was
plotted against the temperature as described before (53).
DNA Pulldown Assay. Oligonucleotides used for the DNA pulldown assay
correspond to the p53/p63/p73 binding site on the CDKN1A promoter (9).
Biotinylated annealed DNA strands were immobilized on streptavidin aga-
rose beads (GE Healthcare) in pulldown buffer (50 mM Tris pH 8.0; 150 mM
NaCl; 0.1% Tween-20), incubated with in vitro translated p63 and washed
four times with pulldown buffer. Bound p63 was eluted with boiling sample
buffer and pulldown efficiency was analyzed by Western blot.
NMR Spectroscopy and Structure Determination. All spectra were recorded at
296 K on Bruker Avance spectrometers (proton frequencies of 600 MHz and
800 MHz) equipped with cryo-probes. The NMR structure of the murine p63
SAM L514F mutant was obtained using combined automated NOE assignment
and structure calculation (54) with the program package CYANA (55). An over-
view of the structural statistics is given in SI Appendix, Table S1. Details about the
recorded spectra and structure calculation are described in SI Appendix. The
accession number for the coordinates and structures factors of murine p63
SAM L514F mutant reported in this manuscript is PDB ID code 5N2O.
Quantification and Statistical Analysis. All datasets derive from at least three
independent experiments unless otherwise indicated. The number of in-
dependent experiments are indicated (n), with the exception of Fig. 3J in
which n indicate number of analyzed animals. Data are presented as the
mean of independent experiments ±SEM or SD as indicated. All statistical
analyses were performed using GraphPad Prism software (version 7.0). In
experiments comparing two samples, paired or unpaired, two-tailed t testing
was performed, whereas when comparing multiple independent samples, one-
way analysis of variance (ANOVA) followed by Tukey’s HSD multiple compari-
son post hoc tests were performed as described in the figure legends. P values
of statistical significance are represented as *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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